Straits Times Index
3,217.41 +10.42 (+0.32%) Nikkei
31,857.62 -14.90 (-0.05%) Hang Seng
17,809.66 +436.63 (+2.51%) FTSE 100
7,608.08 +6.23 (+0.08%) Bitcoin USD
27,027.08 +131.10 (+0.49%) CMC Crypto 200
579.66 +0.90 (+0.15%)
Tandem Diabetes Care, Inc. (0M0F.L)
| Previous close | 20.82 |
| Open | 20.69 |
| Bid | 0.00 x N/A |
| Ask | 0.00 x N/A |
| Day's range | 20.69 - 20.69 |
| 52-week range | 19.96 - 57.92 |
| Volume | |
| Avg. volume | 317 |
| Market cap | 11.711M |
| Beta (5Y monthly) | 0.87 |
| PE ratio (TTM) | 2.32 |
| EPS (TTM) | 0.09 |
| Earnings date | 31 Oct 2023 - 06 Nov 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
Motley Fool2 Stocks Under $25 to Buy and Hold for 10 Years
The company's current lineup includes the t:slim X2 and the newly cleared Mobi Insulin Pump, which management calls "the world's smallest durable insulin delivery system." Despite this progress on the regulatory front, Tandem has been bruised and battered on the stock market over the past year, as its financial results haven't been as good. The company's sales of insulin pumps have declined amid the challenging economy, leading to lower year-over-year revenue growth.
ZacksHere's Why You Should Retain Tandem Diabetes (TNDM) Now
Investors continue to be optimistic about Tandem Diabetes (TNDM) due to the t:slim X2 insulin pump and new product innovations.
Business WireTandem Diabetes Care Announces Upcoming Conference Presentations
SAN DIEGO, August 24, 2023--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced that management will present a company update at the following investor conferences:
